Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents

B W Futscher1, L C Erickson

  • 1Department of Pharmacology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois 60153.

Cancer Research
|January 1, 1990
PubMed

Insights

DNA-damaging chemotherapy drugs can suppress oncogene expression. Alkylating agents altered c-myc and c-fos mRNA levels in colon cancer cells, supporting their potential to reduce transforming gene activity.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Oncogenes play a crucial role in cancer development.
  • Understanding how chemotherapy affects oncogene expression is vital for treatment optimization.
  • The Colo320HSR cell line exhibits amplified c-myc oncogene expression.

Purpose of the Study:

  • To investigate the impact of DNA-damaging chemotherapeutic agents on oncogene mRNA levels.
  • To determine if alkylating agents can suppress the expression of specific oncogenes in colon carcinoma cells.

Main Methods:

  • Utilized three bifunctional alkylating agents: mechlorethamine, L-phenylalanine mustard, and 4-hydroperoxycyclophosphamide.
  • Examined steady-state mRNA levels of c-myc, c-fos, N-ras, and beta-actin in Colo320HSR cells.
  • Employed Northern blot analysis to quantify gene expression changes over a 24-hour period post-treatment.

Main Results:

  • All tested alkylating agents similarly affected gene expression.
  • Transient increases in c-myc and c-fos mRNA were observed immediately after drug removal.
  • Significant downregulation of c-myc and c-fos mRNA occurred 6-12 hours post-treatment, with N-ras and beta-actin largely unaffected.

Conclusions:

  • DNA-damaging alkylating agents can suppress the expression of specific oncogenes like c-myc and c-fos.
  • These findings support the hypothesis that chemotherapy can reduce the activity of transforming genes.
  • The observed modulation of oncogene expression by chemotherapy warrants further investigation for therapeutic strategies.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...